NEW PRODUCTS
| Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
|---|---|---|---|---|
| 171462 | MRTX0902 | 2654743-22-1 | ≧98.0% |  |
| MRTX0902is a potent SOS1 inhibitor which can be used for the therapeutic intervention | ||||
| 20369 | Sunvozertinib ( DZD 9008 ) | 2370013-12-8 | ≧98.0% | _2370013-12-8.png) |
| Sunvozertinib, also known as DZD9008, is an oral, potent, irreversible, and selective | ||||
| 232251 | Brepocitinib ( PF-06700841 ) | 1883299-62-4 | ≧98.0% | _1883299-62-4.png) |
| Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1 | ||||
| 230403 | (R,S)-BI 1015550 | 1423719-27-0 | ≧98.0% | -BI_1015550_1423719-27-0.png) |
| BI 1015550 is a novel PDE4 inhibitor showing a preferential enzymatic inhibition of P | ||||
| 52004 | Belnacasan | 273404-37-8 | 98% | _273404-37-8.png) |
| Belnacasan is a prodrug ofVRT-043198, a caspase-1 inhibitor that was developed by Ver | ||||
| 20302 | VAS3947 | 869853-70-3 | ≧98.0% |  |
| VAS3947 is a selective inhibitor of NADPH oxidase activity in low micromolar concentr | ||||
| 232252 | Brepocitinib Tosylate | 2140301-96-6 | ≧98.0% |  |
| Brepocitinib ( PF-06700841 ) is an orally available, selective inhibitor of non-recep | ||||
| 20368 | SHMT-IN-2 | 2102681-49-0 | ≧98.0% |  |
| SHMT-IN-2 is a serine hydroxymethyltransferase (SHMT) inhibitor, potently inhibiting | ||||
| 20480 | ethyl 5-chloro-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylate | 2359650-50-1 | ≧96.0% |  |
| 230401 | Glycerol phenylbutyrate ( HPN-100 ) | 611168-24-2 | ≧98.0% | .png) |
| Glycerol phenylbutyrate, also known as HPN-100, is under trials in the treatment of c | ||||
| 51905 | CPI-613(Devimistat ) | 95809-78-2 | ≧98.0% |  |
| CPI-613( Devimistat ) is an E1 pyruvate dehydrogenase (PDH) modulator that prevents c | ||||
| 16122906 | Brivaracetam | 357336-20-0 | 98% |  |
| Brivaracetam, also known as UCB 34714, is a chemical analog of levetiracetam, is a ra | ||||